The Evolution of Real-World Endpoints in Oncology R&D

Escalating R&D investments in oncology are met with stagnating clinical success rates, a paradox driven by the challenge of accurately measuring therapeutic progress with traditional, fragmented real-world data. This white paper explores how to improve endpoint fidelity to de-risk development and raise the probability of technical and regulatory success.